Dr. Gervasio Lamas, a Harvard-trained cardiologist, once scoffed at a patient’s request to consider chelation therapy for his cardiac condition. However, upon further consideration, even Dr. Lamas was bothered by how quickly he had discredited something he had not investigated, and he set about to remedy that.
Seventeen years later, Dr. Lamas made the study a reality, despite encountering a great deal of professional and financial hardship to do so. The results of the $30 million double-blind study, released in 2013, were intriguing: chelation is safe and somewhat effective for heart disease. The study covered 1,700 Canadian and American patients over age 50 that had a recent heart attack; almost one-third of that group also had diabetes. Half the group received EDTA, and the other half, a vitamin and mineral infusion. The chelation group had an 18 per cent reduced risk for heart attack, stroke, hospitalization for angina, or the need for bypass surgery. The real standout result was in those with diabetes—a 41 per cent reduction in recurrent heart events, and a 43 per cent reduction in deaths. Dr. Lamas published his findings in the Journal of the American Medical Association, where they were met with skepticism and criticism.
In 2016, a determined Dr. Lamas made plans to do another trial called TACT 2 (Trial to Assess Chelation Therapy), this time focusing on those with diabetes. This time, the U.S. National Institutes of Health would provide $37 million. Some, such as Steven L. Salzberg of John Hopkins University, remain skeptical. Salzberg stated there are “better ways to use this money.” Dr. Lamas no longer takes such criticisms personally, though, and persevered with arranging the second study. Currently, 1,400 patients across Canada and the US are being recruited to participate. The Canadian branch of the study will be headed by Dr. Michael Farkouh, a cardiologist practicing out of the Peter Munk Cardiac Centre in Toronto. Dr. Farkouh admitted that traditional medicine needs to incorporate out-of-the-box thinking. Dr. Diana Visentin, an internal medicine specialist who trained for 2 years to participate with the study, agreed. She said, “Diabetes is an epidemic. The prevalence is increasing, the tsunami of complications is still to come…and if we can slow that tide, it will be a benefit to all of us.”Dr. Lamas’ team is hoping to have results of the current study in about 4 years.
Of course, for those in the natural industry who have known about chelation for some time, these results are encouraging, but hardly surprising. Even in 1955, the Providence Hospital in Detroit found that EDTA dissolved “metastatic calcium,” which deposits in unwanted places such as joints, kidneys, and arteries. And, besides clearing out arteries, EDTA also makes bones stronger. Dr. Garry Gordon, known as the father of the modern chelation movement, found that the more chelation therapy he gives a patient, the less osteoporosis and age-related calcium accumulation that patient has. These are just some of the benefits of chelation therapy.
Still, not everyone can commit to IV style chelation, which is why Life Choice CLAW-OCHMB is ideal. CLAW combines EDTA with a synergistic blend of medicinal ingredients designed to safely pull heavy metals and calcium deposits out of the body—all in a V-capsule. We have 2 key recommendations with CLAW:
- 1-Use one bottle per every 10 years of life. So, for example, a 40-year-old would use 4 bottles back to back, and then to be repeated every 5 years.
- 2-Be sure to also take a high-quality multi-mineral blend with K2, such as Opti-Cal/Mag Complex. Because CLAW depletes all minerals from the body both organic and non-organic, it needs to be replaced (with a high quality multi-mineral) to minimize mineral depletion symptoms such as joint pains and toothaches.